No Data
No Data
Express News | 60 Degrees Pharma Announces Irb Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients With Persistent Babesia Microti Despite Prior Treatment
Express News | First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
Express News | 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients With Acute Babesiosis
Express News | Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) reported today their financial results for the first fiscal quarter of the 2024 year, ended March 31, 2024.
10-Q: Quarterly report
No Data